*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.1
Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.
Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.
Based on prescription data collected from April to September 2023.
†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.
ARR, annualized relapse rate; CDP, confirmed disability progression; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis; SC, subcutaneous.